Describe the role of FLT3 mutations and biomarker testing in AML pathogenesis and treatment selection for newly diagnosed patients. 2. Outline diìerences in mechanism of action and personalized treatment considerations for selecting among currently available FLT3 inhibitors 3. Evaluate clinical trial data regarding new and emerging FLT3 inhibitors and combination therapies in patients newly diagnosed with AML 4. Integrate FLT3 inhibitors in clinical practice for patients newly diagnosed with AML 5. Deíne anticipated TRAE proíles associated with available FLT3 inhibitors and approaches for their monitoring and management
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2025-01-02 06:00:00
- End Date: 2025-01-02 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 75000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest